BTAI

BioXcel Therapeutics, Inc. [BTAI] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

BTAI Stock Summary

Top 10 Correlated ETFs

BTAI


Top 10 Correlated Stocks

BTAI


In the News

02:52 29 Mar 2024 BTAI

7 Short-Squeeze Stocks That Could Send the Bears Into Panic-Mode

There's a simple reason why short-squeeze stocks to buy represent a powerful catalyst: they're intuitive and easier to engage. Buying something and hoping that it appreciates in value represents an organically sensible strategy.

07:00 29 Mar 2024 BTAI

BioXcel Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on March 12, 2024

NEW HAVEN, Conn., March 01, 2024 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience and immuno-oncology, today announced that it will release its fourth quarter and full year 2023 financial results on Tues., March 12, 2024, before the open of the U.S. financial markets. BioXcel Therapeutics' management team will also host a conference call and webcast at 8:00 AM ET that day to discuss the Company's financial results and provide a general business update.

09:05 29 Mar 2024 BTAI

Why Is BioXcel Therapeutics (BTAI) Stock Down 26% Today?

BioXcel Therapeutics (NASDAQ: BTAI ) stock is taking a beating on Friday after the commercial-stage biopharmaceutical company announced a proposed underwritten public offering for its shares. This public offering includes $60 million shares of BTAI stock.

06:40 29 Mar 2024 BTAI

7 Penny Stocks With Low Floats and High Short Interest

There are many ways to approach penny stocks, but one that has gained popularity in recent years focuses on stocks in this category that are prime candidates for a “short squeeze.” A typical short squeeze candidate has a high level of short interest, or percentage of outstanding float sold short.

10:41 29 Mar 2024 BTAI

BioXcel Therapeutics stock plummets as 3Q earnings fall short of expectations

BioXcel Therapeutics Inc (NASDAQ:BTAI) shares fell almost 35% after it reported a revenue miss and greater than forecast loss for the third quarter. The New Haven, Connecticut-based biopharmaceutical company reported sales of $341,000, up from $137,000 in the year-ago quarter but below estimates of $840,000.

02:11 29 Mar 2024 BTAI

5 Most Active Penny Stocks Today & Why They're Moving Now

Penny stocks are the wild west of the stock market. Fast-paced, unpredictable, and laden with potential treasures.

02:18 29 Mar 2024 BTAI

Penny Stocks To Buy Today? 4 To Watch Now

Ready to dive into the volatile world of penny stocks? You've got your work cut out for yourself if this is your first foray into the stock market.

12:09 29 Mar 2024 BTAI

4 Penny Stocks To Watch Today With Big News, Time To Buy?

Trading penny stocks can be a risky endeavor, but having access to quality news and information can help mitigate some of that risk. As an investor or trader, it's critical to understand how news events can impact penny stocks and how to use news to your advantage when developing your trading strategy.

03:06 29 Mar 2024 BTAI

3 Penny Stocks To Buy For Under $5, Are They Worth It?

Penny stocks are defined as stocks trading for under $5. They typically include start-up or emerging-growth stage companies starting from the grassroots.

09:19 29 Mar 2024 BTAI

5 Hot Penny Stocks To Watch In The Stock Market Today

Whether you're looking for the best penny stocks to buy, the most active stocks today, or just trying to plan out your next long-term investment, understanding things like stock market news and events is important.

BTAI Financial details

Company Rating
Neutral
Market Cap
85.37M
Income
-177.28M
Revenue
1.38M
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
183
Optionable
No
Shortable
Yes
Earnings
06 May 2024
P/E
-0.38
Forward P/E
-1.71
PEG
5.82
P/S
65.29
P/B
-2
P/C
-
P/FCF
-0.49
Quick Ratio
2.3
Current Ratio
2.51
Debt / Equity
-
LT Debt / Equity
-2.45
-
-
EPS (TTM)
-6.09
EPS next Y
-1.65
EPS next Q
-0.76
EPS this Y
0.33%
EPS next Y
-72.98%
EPS next 5Y
-98.93%
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
10.26%
EPS Q/Q
-55.81%
-
-
-
-
SMA20
-12.73%
SMA50
4.85%
SMA100
-21.51%
Inst Own
31.42%
Inst Trans
0.52%
ROA
-212%
ROE
-897%
ROC
-3.36%
Gross Margin
55%
Oper. Margin
-16490%
Profit Margin
-17159%
Payout
-
Shs Outstand
33.63M
Shs Float
23.62M
-
-
-
-
Target Price
34
52W Range
1.91-29.56
52W High
-90.28%
52W Low
+182%
RSI
45.71
Rel Volume
0.21
Avg Volume
1.61M
Volume
335.5K
Perf Week
3.68%
Perf Month
-9.03%
Perf Quarter
7.22%
Perf Half Y
2.17%
-
-
-
-
Beta
0.416
-
-
Volatility
0.03%, 0.24%
Prev Close
-2.08%
Price
2.82
Change
0%

BTAI Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2023-12-31

Metric History 2019-12-312020-12-312021-12-312022-12-31 2023-12-31
2.02K2.02K2.02K2.02K2.02K
Revenue per share
0000.010.05
Net income per share
-1.99-3.78-4.04-6.13-6.15
Operating cash flow per share
-1.67-3.06-3.12-4.83-5.32
Free cash flow per share
-1.73-3.07-3.13-4.84-5.32
Cash per share
1.999.838.836.922.24
Book value per share
1.659.538.412.74-1.94
Tangible book value per share
1.659.538.412.74-1.94
Share holders equity per share
1.659.538.412.74-1.94
Interest debt per share
0.070.080.053.653.93
Market cap
237.98M1B536.16M601.76M85.93M
Enterprise value
206.59M790.27M304.59M502.19M121.75M
P/E ratio
-7.36-12.22-5.03-3.5-0.48
Price to sales ratio
0001.6K62.27
POCF ratio
-8.72-15.1-6.53-4.45-0.55
PFCF ratio
-8.45-15.03-6.49-4.44-0.55
P/B Ratio
8.854.852.427.84-1.52
PTB ratio
8.854.852.427.84-1.52
EV to sales
0001.34K88.22
Enterprise value over EBITDA
-6.06-9.6-2.85-3.19-0.73
EV to operating cash flow
-7.57-11.91-3.71-3.71-0.79
EV to free cash flow
-7.34-11.85-3.69-3.71-0.79
Earnings yield
-0.14-0.08-0.2-0.29-2.08
Free cash flow yield
-0.12-0.07-0.15-0.23-1.8
Debt to equity
0.040.010.011.23-1.79
Debt to assets
0.030.010.010.461.37
Net debt to EBITDA
0.922.572.170.63-0.21
Current ratio
4.0318.3313.986.172.65
Interest coverage
0-3.05K-2.67K-19.44-12.59
Income quality
0.830.810.770.820.87
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
000183.360
Research and developement to revenue
000243.361.11
Intangibles to total assets
00000
Capex to operating cash flow
0.0300.0100
Capex to revenue
000-0.37-0.01
Capex to depreciation
-5.58-1.68-1.5-0.43-0.06
Stock based compensation to revenue
00046.2313.49
Graham number
8.5928.4827.6519.4516.38
ROIC
-1.13-0.39-0.48-0.96-3.73
Return on tangible assets
-0.89-0.37-0.45-0.83-2.43
Graham Net
1.419.228.162.35-2.2
Working capital
25.64M205.22M216.3M169.97M44.88M
Tangible asset value
26.9M206.7M221.67M76.78M-56.51M
Net current asset value
24.61M203.83M215.2M73.79M-58.07M
Invested capital
0.040.010.011.23-1.79
Average receivables
57.5K00124K159.5K
Average payables
3.28M4.47M4.33M7.45M11.94M
Average inventory
000992.5K1.99M
Days sales outstanding
000241.3918.78
Days payables outstanding
11.59K7.73K5.75K186.66K3.96K
Days of inventory on hand
00036.23K576.76
Receivables turnover
0001.5119.44
Payables turnover
0.030.050.0600.09
Inventory turnover
0000.010.63
ROE
-1.2-0.4-0.48-2.243.17
Capex per share
-0.05-0.01-0.0200

Quarterly Fundamentals Overview

Last date of statement is 2023-12-31 for Q4

Metric History 2022-12-312023-03-312023-06-302023-09-30 2023-12-31
2.02K2.02K2.02K2.02K2.02K
Revenue per share
0.010.010.020.010.01
Net income per share
-2.07-1.78-1.83-1.72-0.76
Operating cash flow per share
-1.38-1.83-1.31-1.280
Free cash flow per share
-1.38-1.83-1.31-1.280
Cash per share
6.95.784.373.070
Book value per share
2.741.850.2-1.390
Tangible book value per share
2.741.850.2-1.390
Share holders equity per share
2.741.850.2-1.390
Interest debt per share
3.463.483.463.530
Market cap
602.9M533.97M194.39M74.05M86.87M
Enterprise value
503.33M464.54M164.64M83.71M0
P/E ratio
-2.59-2.62-0.91-0.37-0.98
Price to sales ratio
2.53K2.59K425.35217.15231.05
POCF ratio
-15.6-10.2-5.09-1.970
PFCF ratio
-15.6-10.2-5.09-1.970
P/B Ratio
7.8510.0733.15-1.820
PTB ratio
7.8510.0733.15-1.820
EV to sales
2.11K2.26K360.25245.480
Enterprise value over EBITDA
-9.7-9.4-3.28-1.950
EV to operating cash flow
-13.03-8.87-4.31-2.230
EV to free cash flow
-13.03-8.87-4.31-2.230
Earnings yield
-0.1-0.1-0.28-0.68-0.26
Free cash flow yield
-0.06-0.1-0.2-0.510
Debt to equity
1.231.8116.68-2.460
Debt to assets
0.460.530.710
Net debt to EBITDA
1.921.40.59-0.220
Current ratio
6.176.163.982.510
Interest coverage
-18.11-15.21-16.08-14.85-5.79
Income quality
0.70.990.710.740
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
86.82114.5446.0962.620
Research and developement to revenue
136.38134.9559.0257.5326.42
Intangibles to total assets
00000
Capex to operating cash flow
00000
Capex to revenue
00-0.0400
Capex to depreciation
00-0.2500
Stock based compensation to revenue
19.1123.6713.411.770
Graham number
11.298.622.887.340
ROIC
-0.33-0.33-0.54-0.860
Return on tangible assets
-0.28-0.28-0.38-0.50
Graham Net
2.351.38-0.19-1.690
Working capital
169.97M148.51M103.49M59.33M0
Tangible asset value
76.78M53.01M5.86M-40.61M0
Net current asset value
73.79M50.17M4M-42.32M0
Invested capital
1.231.8116.68-2.460
Average receivables
2.88M265.5K357K583K0
Average payables
8.05M8.99M9.47M10.94M0
Average inventory
1.7M1.97M1.94M1.97M0
Days sales outstanding
93.78123.6484.88193.990
Days payables outstanding
102.28K77.42K38.78K1.88K0
Days of inventory on hand
19.85K19.52K6.66K354.730
Receivables turnover
0.960.731.060.460
Payables turnover
0000.050
Inventory turnover
000.010.250
ROE
-0.76-0.96-9.131.240
Capex per share
00000

BTAI Frequently Asked Questions

What is BioXcel Therapeutics, Inc. stock symbol ?

BioXcel Therapeutics, Inc. is a US stock , located in New haven of Ct and trading under the symbol BTAI

Is BioXcel Therapeutics, Inc. buy or a sell ?

3 stock analysts have 3 predictions with a medium analyst target price of $34. The lowest prediction is $4 and the highest is $73

What is BTAI stock prediction ?

What is BioXcel Therapeutics, Inc. stock quote today ?

BioXcel Therapeutics, Inc. stock price is $2.82 today.

Is BioXcel Therapeutics, Inc. stock public?

Yes, BioXcel Therapeutics, Inc. is a publicly traded company.

Something similar

Top by Market Cap
Top Correlated ETFs
Top Correlated Stocks
Similar Market Cap